Patient Support Helpline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

For Healthcare Providers

ZERO is proud to partner with accredited medical education providers, many of which offer prostate cancer continuing medical education (CME) hours.

Podcast: Which mCSPC patients benefit from early treatment intensification? (no CMEs offered)

In this podcast, you’ll hear Dr. Shilpa Gupta, MD and Dr. Fabio Schutz review patient cases to explore which patients with metastatic castration-sensitive prostate cancer (mCSPC) benefit from early treatment intensification.

They discuss how to apply key data from ARASENS and PEACE-1 in clinical practice, triplet therapy as the new standard of care, and the patient subgroups that benefit the most from early treatment intensification.

The Role of the Nurse in nmCRPC Patient Management (no CMEs offered)

In this video, Research Nurse Coordinator Pablo Peinado discusses selecting treatments for nmCRPC in clinical practice to minimize the impact on the patient’s quality of life, and how nurses can support and educate their patients, so they know what to expect during treatment.

Podcast: PARP Inhibitors Alone or In Combination with Novel Hormonal Agents in Prostate Cancer (no CMEs offered)

In this podcast series, GU oncologists discuss PARP inhibitors for prostate cancer, given alone or in combination with novel hormonal agents (NHAs). Listen to episodes 1 and 2 to hear Dr. Elena Castro and Dr. Neal Shore share their views and discuss the clinical implementation of PARP inhibitor monotherapy for prostate cancer patients and PARP inhibitors and NHA combination therapy for patients with mCRPC.  Neeraj Agarwal, MD, and Tanya Dorff, MD, continue the conversation in episode 3 and will cover the latest data from ASCO GU 2023.

Expanding Use of Hormonal Therapeutic Strategies in Prostate Cancer: Clinical Evidence and Practical Considerations for Individualized, Patient-Centered Care

Learn how hormonal therapy and treatment intensification strategies are changing outcomes for patients with prostate cancer by joining Matthew R. Smith, MD, PhD, Neeraj Agarwal, MD, and Tanya Dorff, MD. Produced in partnership with PeerView Institute for Medical Education, this in-person (at the ASCO GU 2023 Symposium) and virtual event featured best practices for bringing guideline-recommended and emerging strategies to the clinic and engaging patients, caregivers, and other colleagues in personalized, collaborative care.

PARP Inhibitors in Prostate Cancer and the Rationale Behind Combination Treatment

In this micro e-learning program, providers will learn about PARP inhibitors in prostate cancer from independent experts Assoc. Prof. Alicia Morgans, MD, MPH, and Dr. Pasquale Rescigno. Module 1 covers the use of PARP inhibitors as monotherapy in advanced prostate cancer, and in module 2, the experts will explore the rationale behind combination treatment with anti-androgens. After watching the videos, take the assessments to earn CME credits. This activity was developed through a partnership with COR2ED and was released in January 2023.

Case Review: Team-Based Approaches to Optimize Androgen Deprivation Therapy in Advanced Prostate Cancer

Prostate cancer experts Alicia K. Morgans, MD, MPH, Pranav Sharma, MD, and Diane G. Cope, PhD, APRN, BC, AOCNP provide learners with skills and knowledge to work more closely with members of the interprofessional team to individualize treatment for patients with advanced prostate cancer so they may optimize their use of androgen deprivation therapy, or ADT. This activity was developed through a partnership with Medscape and was released on November 22, 2022. Available until November 22, 2023.

Creating a Roadmap for Modern Prostate Cancer Care: How to Use the Most Recent Evidence on Novel Therapeutic Strategies and Shared Decision Making to Personalize Patient Care

Prostate cancer experts Alicia K. Morgans, MD, MPH, and Mark T. Fleming, MD highlight how a prostate cancer care team can use the latest clinical evidence, treatment guidelines, and consensus recommendations to improve outcomes for patients with prostate cancer and will give practical insights on applying next-generation anti-androgen agents, PARP inhibitors, and chemotherapy to the prostate cancer treatment landscape. By providing a “roadmap” to the multiple pathways of prostate cancer management, this program serves as a resource for professionals interested in the present and future applications of new science in patient care. This activity was planned and implemented through a partnership with Medical Learning Institute, Inc., and PVI, PeerView Institute for Medical Education. For more information and to view the webinar and practice aids, click here. Available until October 30, 2023.

Optimizing Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer

In this virtual event, a panel of experts in prostate cancer discuss the practical considerations of oral therapies and common adverse events associated with approved agents for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). This activity is intended for oncologists, urologists, nurses, nurse practitioners (NPs), pharmacists, and other interprofessional healthcare providers (HCPs) practicing globally who care for individuals with prostate cancer. This activity was developed through a partnership with Medscape and presented live on June 22, 2022. For more information and to view the webinar, click here. Available until July 26, 2023.

Expanding the Role of Radiopharmaceuticals for Prostate Cancer Management

Join urologists and prostate-cancer experts Dr. Neal Shore and Dr. Michael Gorin to discuss the role of approved and emerging radiopharmaceuticals in the optimal management of prostate cancer. Panelists will compare newer radiotracers with conventional imaging and review recent safety and efficacy data on the integration of molecular imaging into all stages of prostate cancer in this 60 minute CME opportunity. This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with ZERO. Click here for more information and to view the webinar. Available until May 3, 2023.

The Prostate Cancer Clinical Masterclass Series (no CMEs offered)

The Prostate Cancer Clinical Masterclass Series is a free, on-demand education series for clinicians, co-chaired by Dr. Sumit Subudhi and Dr. Gert Attard. It boasts a faculty of 24 guest presenters who are leading clinicians within the global prostate cancer space. This twelve-month initiative consists of monthly episodes which are led by two guest presenters, who will each deliver a fifteen-minute presentation, followed by a group discussion with the co-chairs. The Prostate Cancer Clinical Masterclass Series does not offer CME credits.

ZERO’s Prostate Cancer Support Programs

For more information on ZERO’s support programs for prostate cancer patients and their loved ones, including our ZERO360 comprehensive patient support program – staffed by trained case managers, Us TOO support groups, and MENtor programs, view our Support Programs postcard.

ZERO360 Postcard

Are you a healthcare provider who would like to have ZERO’s materials in your office? Request your free prostate cancer educational literature here!